Doctors Only for Summaries and Alerts

Diving deeper into

Function Health

Company Report
Function intentionally limits doctor involvement to generating summaries and handling critical alerts, without providing direct consultations or prescriptions.
Analyzed 6 sources

Keeping doctors out of the main workflow is what lets Function sell a broad preventive testing product at consumer internet scale instead of becoming a telehealth clinic. The member pays upfront for data collection and interpretation, not for ongoing medical care. Quest handles the blood draw network, clinicians review results and contact people on critical findings, and the product experience centers on dashboards, summaries, and follow up testing rather than visits, diagnosis, or prescriptions.

  • This makes the business model much lighter than prescription telehealth. Hone Health is built around lab work that feeds into doctor evaluation and mail order hormone treatment, so more of its cost structure and operations sit inside clinical care. Function instead uses clinicians mainly as an oversight layer on top of testing and software.
  • The tradeoff is deliberate. By not writing prescriptions or managing treatment, Function can package many biomarkers, add MRI and genomics over time, and keep the product feeling like an always on health record. That is closer to a consumer software subscription than a medical practice, even though licensed clinicians still review every result and handle urgent issues.
  • This also explains why Ezra fits cleanly. A fast $499 MRI adds another paid diagnostic data stream into the same member account without requiring Function to build specialist consult workflows. Hims moved the other way, acquiring Trybe Labs to feed a prescribing engine and broader care delivery stack.

The next step is a broader diagnostic bundle where blood, imaging, wearables, and genetics all flow into one recurring membership. If Function keeps doctor touchpoints narrow and reserved for safety review, it can keep expanding the number of tests and the frequency of engagement without taking on the full cost and regulatory weight of direct treatment.